证券代码：300233 证券简称：金城医药 公告编号：2025-045 山东金城医药集团股份有限公司 一、药品基本情况 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司及 控股子公司广东金城金素制药有限公司分别收到国家药品监督管理局下发的《药 品注册证书》，现将有关情况公告如下： | 产品 | 剂型 | 注册 | | 规格 | | 包装 | 药品批准 | 上市许 可持有 | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 分类 | | | | 规格 | 文号 | | | | | | | | | | | | 人 | | | | | | | | | | | | 根据《中华人民共和国药品管 | | | | | | | | | | | 理法》及有关规定，经审查， | | | | | | | | | | | 本品符合药品注册的有关要 | | | | | | | | | ...

2025年5月30日，公司与中国工商银行股份有限公司淄博淄川支行签署了《保 证合同》，为金城生物借款提供连带责任担保，担保债权之最高本金余额为人民币 500万元整(大写：伍佰万元整)。 | 被担保方 | 经审议的 | | 本次担保前对 | | 本次担保后对 | | 已使用担保额 | 剩余可用 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 担保额度 | | 被担保方的担 | | 被担保方的担 | | 度（含本次） | 额度 | | | | | | 保余额 | | 保余额 | | | | | | 金城生物 | 20,000 | 万元 | 5,650 | 万元 | 6,150 | 万元 | 11,500 万元 | 8,500 | 万元 | 二、被担保人基本情况 证券代码：300233 证券简称：金城医药 公告编号：2025-044 （一）基本信息 山东金城医药集团股份有限公司 6、经营范围：许可项目：药品生产；药品批发；食品添加剂生产；饲料添加 剂生产；食品销售；食品生产；药品进出口；保健食品生产；饲料生产。（依法须 经批 ...

注：汇海医药尚未发生实际借款业务，故本次担保后对被担保方的担保余额尚未发生变动。 证券代码：300233 证券简称：金城医药 公告编号：2025-043 山东金城医药集团股份有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十四次 会议审议通过了《关于预计2025年度担保额度的议案》，并经公司2024年年度股东 大会审议通过。公司及子公司对外担保总额不超过人民币15.3亿元，其中为山东汇 海医药化工有限公司（以下简称"汇海医药"）提供担保不超过人民币4亿元。 一、担保情况概述 2025年5月26日，公司与招商银行股份有限公司淄博分行签署了《最高额不可 撤销担保书》，为汇海医药借款提供连带责任担保，担保债权之最高本金余额为人 民币5,000万元整(大写：伍仟万元整)。 | 被担保方 | 经审议的 | 本次担保前 | 本次担保后 | 已使用担保 | 剩余可用 | | --- | --- | --- | --- | --- | --- | | | 担保额度 | 对被担保 ...

Group 1 - The genetically modified (GM) concept sector declined by 2.81%, ranking among the top declines in concept sectors as of the market close on May 22 [1] - Key companies within the GM sector that experienced significant declines include KQ Bio, Jincheng Pharmaceutical, and Batian Agricultural [1] - The GM concept sector saw a net outflow of 171 million yuan in main funds today, with 13 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The stock with the highest net outflow was Dabeinong, with a net outflow of 45.6868 million yuan, followed by Jincheng Pharmaceutical and Batian Agricultural with net outflows of 35.9827 million yuan and 21.2855 million yuan, respectively [2] - Other companies with notable net outflows include Qianyuan High-Tech and Nongfa Seed Industry, with outflows of 13.8355 million yuan and 11.1082 million yuan, respectively [2] - Conversely, Shennong Seed Industry and Fengle Seed Industry were among the few stocks with net inflows, receiving 9.7587 million yuan and 0.8193 million yuan, respectively [2]

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

Group 1: Company Operations and Product Development - The production of astaxanthin is currently undergoing safety certification review, with plans for market launch initially set for 2024 but now delayed to 2025 [2] - The company is actively communicating to expedite the approval process for astaxanthin [2] - Glutathione is being positioned as a raw material for downstream pharmaceutical production, with licenses obtained for its use in functional foods and health products [3] Group 2: Market Conditions and Financial Performance - The company is managing stable raw material costs and enhancing cost control measures to mitigate the impact of fluctuating crude oil prices on profits [2] - The first quarter profit saw a year-on-year decline, attributed to price reductions in some products due to procurement policies and intensified industry competition [5] - The overall business impact from US-China trade tensions is currently assessed as minimal, with ongoing monitoring of tariff policy changes [5] Group 3: Product Pricing and Market Demand - The price of glutathione has not seen significant changes recently, despite market fluctuations and varying customer requirements [5] - The company is exploring the potential for glutathione to be classified as a new resource food, which could significantly increase demand [2] - The company is tracking developments in the new tobacco sector, focusing on nicotine therapy and harm reduction [5]

Group 1 - Tonghua Dongbao has received approval from Nicaragua's National Health Regulatory Authority for its recombinant human insulin injection, which is expected to enhance the company's international market presence and brand image [1] - The diabetes patient population in Nicaragua is projected to reach 377,000 by 2024, with an 8.7% prevalence rate among adults aged 20-79, indicating a significant market opportunity for the company [1] - The average annual expenditure per diabetes patient in Nicaragua is estimated at $587, highlighting the potential revenue generation from the new product [1] Group 2 - Haobor's response to the 2024 annual report inquiry reflects the company's commitment to regulatory compliance and transparency, addressing concerns regarding its distribution model and dealer management [2] - The detailed analysis of dealer numbers and management policies demonstrates the stability and rationality of the company's business model, which may alleviate investor concerns [2] - Continuous optimization of dealer management is expected to provide strong support for the company's long-term development [2] Group 3 - Kangji Medical has decided to terminate the sale of a subsidiary and has reached a settlement agreement with the buyer, which includes the return of company records and a refund of 5 million yuan [3] - The company expects to realize approximately 39.3 million yuan in gains from a land recovery agreement with government agencies, indicating effective management of complex transactions [3] - The resolution of this transaction is likely to stabilize investor confidence and positively impact the company's long-term growth prospects [3] Group 4 - Jincheng Pharmaceutical has signed a licensing and distribution agreement with UK-based Theramex HQ UK Limited for the hormone replacement therapy product Bijuva, aimed at addressing estrogen deficiency symptoms in postmenopausal women [4] - This collaboration aligns with the company's strategy to enhance its offerings in women's health and strengthen partnerships with international pharmaceutical firms [4] - The agreement is expected to expand the company's product portfolio in the women's health sector and improve its brand influence in this market [4]

证券代码：300233 证券简称：金城医药 公告编号：2025-042 山东金城医药集团股份有限公司 关于签署权益许可和经销协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本协议的签署不会对公司本年度财务状况及经营业绩构成重大影响。 2、本次合作不构成关联交易，亦不构成重大资产重组。 一、协议签署情况 山东金城医药集团股份有限公司（以下简称"公司"或"金城医药"）近日与 Theramex HQ UK Limited (以下简称"Theramex")签署了《权益许可和经销协议》 （以下简称"本协议"或"协议"）。双方就用于绝经后妇女雌激素缺乏症状的连 续联合激素替代疗法（HRT）的雌二醇黄体酮软胶囊（以下简称"Bijuva"，为其 商品名）在中国境内的权益许可和经销协议达成合作，金城医药获得该产品在中国 大陆、香港和澳门的独家排他的商业化权益。 本次签署合作协议不涉及关联交易，亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。本协议无需提交公司董事会、股东大会审议批准。 二、协议对方介绍 5、履约能力分析：Theramex ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司 关于参加 2025 年山东辖区上市公司投资者网上集体 接待日活动的公告 为进一步加强与投资者的互动交流，山东金城医药集团股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演APP,参与本次互动交流。活动时间为2025年5月15日（周四）15:00-16:30。 届时公司董事会秘书朱晓刚先生、财务总监刘静女士将在线就公司 2024 年度业 绩、公司治理、发展战略、经营状况和可持续发展等投资者关心的问题，与投资 者进行沟通与交流，欢迎广大投资者踊跃参与！ 证券代码：300233 证券简称：金城医药 公告编号：2025-041 特此公告。 2025 年 5 月 12 日 - 1 - 山东金城医药集团股 ...

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]